Dawex and Innovalia Group Join Forces to Accelerate the Deployment of Data Exchange Solutions in Spain
Dawex, the leader in data exchange solutions, and Innovalia Group, a strategic group of technology companies specializing in digital transformation solutions, have signed a strategic collaboration agreement to drive the development of secure and sovereign data spaces in the Spanish market through a comprehensive range of products and services.
The collaboration brings together two strong and complementary areas of expertise: Dawex’s technological leadership in Data Exchange and the Innovalia Group’s extensive knowledge of the Spanish industrial sector. Dawex and the Innovalia Group are joining forces to offer joint value propositions to large companies, SMEs and public entities, interested in deploying their own digital ecosystems and secure, trusted data spaces.
Dawex brings its extensive technology, business and regulatory expertise in creating secure and trusted data ecosystems, such as Corporate Data Hubs, Data Marketplaces and Industry Data Spaces, to create data spaces and improve competitiveness, market efficiency and value chain resilience.
The Innovalia Group contributes its deep knowledge of the Spanish market, its ability to provide advanced IT and consulting services, and a network of technology SMEs that strengthen the implementation and scalability of the joint solutions.
The agreement primarily focuses on the Spanish market, with an initial goal of addressing the energy, manufacturing, agri-food, construction, retail, and mobility sectors.
“This strategic collaboration between Dawex and the Innovalia Group is an essential step toward accelerating the development of secure and sovereign data spaces across the Spanish market,” says Fabrice Tocco, Co-CEO of Dawex. “Together, we are empowering Spanish organizations across all major sectors to reach new levels of efficiency and innovation by bringing software solutions for the creation of resilient and high-performance data spaces and data marketplaces, in partnership with the Innovalia Group located in many regions in Spain.”
According to Jesús de la Maza, President of Innovalia Group, “With the signing of this agreement and the integration of Dawex solutions into our portfolio, we now possess unique capabilities to help companies adopt data exchange and governance solutions that enable them to take a significant step forward in improving their business processes and launching AI-driven initiatives.”
About Dawex
Dawex is the leader in Data Exchange solutions to distribute or share data products, with trust, security, traceability and in compliance with data regulations. With Dawex Data Exchange technology, organizations create data ecosystems such as Corporate Data Hubs, Data Marketplaces and Industry Data Spaces to improve competitiveness, market efficiency and value chain resilience. At the invitation of the United Nations, Dawex joins the Data Expert group of the United Nations Environment Program. Awarded Technology Pioneer by the World Economic Forum, Dawex is also the initiator of an international standardization program on Trusted Data Transaction. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
About Innovalia Group
Headquartered in Bilbao and with more than 35 years of experience, the Innovalia Group is an international alliance of technology-based companies whose main goal is to provide tools and solutions for digital transformation. The group brings together multidisciplinary teams to offer a wide range of services and products tailored to the needs of both public and private sector clients, following an open innovation model. As a strategic group, Innovalia has established itself as a key player in business digitalization. www.innovalia.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251110019292/en/
Contacts
Press: Isabelle Joulot, Vice President Communications & Marketing
press@dawex.com
Press: Alicia González, Marketing Manager
info@innovalia.org
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom